

Enc 4 Appx 3

Clinical Expert Summary Cefuroxime (Aprokam[®]) 50 mg powder for solution for injection

Cefuroxime (Aprokam[®]) for antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery.

1. Existing guidelines

Reference was made to the following guidelines:

- The Royal College of Ophthalmologists Cataract Surgery Guidelines (September 2010)
- European Society of Cataract and Refractive Surgeons Guidelines for Prevention & Treatment of Endophthalmitis Following Cataract Surgery (2013)
- National Institute for Health and Care Excellence guidelines in development for the management of cataracts in adults (anticipated publication October 2017)

2. Disease prevalence/incidence

The number of admissions for cataract surgery in Wales was estimated to be more than 16,000 a year.

3. Current treatment options

Intracameral cefuroxime at the end of cataract surgery is the predominant treatment in Wales for the indication detailed above. Aprokam[®] is already in use in health boards in NHS Wales. Treatment options for cefuroxime include:

- Aprokam[®], a single use vial containing 50 mg powder for solution for injection.
- Unlicensed intracameral prefilled syringe of cefuroxime available from specials manufactures.
- Off-label cefuroxime for injection, which is prepared in the operating theatre by serial dilution for intracameral injection.

Alternative treatments considered in cases of documented allergic reaction include vancomycin in irrigating solution, vancomycin injection and moxifloxacin injection.

4. Unmet needs

Experts noted that Aprokam[®] is a licensed form of cefuroxime which would minimise the risk of human error and contamination associated with the preparation of off-label cefuroxime intracameral injections.

5. Knowledge of product in given indication

Experts noted that Aprokam[®] was already in use in departments in NHS Wales.

It should be noted that the experts involved in compiling this response declared no interests in relation to cefuroxime (Aprokam[®]) for the indication under consideration.